Abstract: Objective The aim of this study was to investigate the safety and efficacy of elbavir/granavir antiviral regimen in the treatment of patients with chronic hepatitis C (CHC) and chronic renal disease (CRD). Methods 56 patients with CHC and CRD undergoing hemodialysis were admitted to our hospital between February 2018 and November 2023, and all received albavir/gravir antiviral treatment for 12 weeks. Serum HCV RNA loads were assayed by RT-PCR, and rapid virologic response (RVR), end treatment of virologic response (ETVR) and sustained virologic response (SVR) were recorded. Results Among 56 patients with CHC and CRD in our series, the infected genotypes of HCV included 1b in 11 cases(19.6%), 2a in 39 cases (69.6%) and 1b/2a in 6 cases (10.7%); the RVR, ETVR and SVR were 73.2%, 91.1% and 85.7%, respectively; by end of antiviral treatment, serum ALT, AST, HCV RNA loads, BUN and sCr levels were 30.6(29.7, 37.5)U/L, 32.7(18.7, 36.4)U/L, 0.8(0.4, 3.1)lg copies/ml, (7.8±1.8)mmol/L and 132.7(85.7, 262.4)μmol/L, all significantly lower than [50.5(40.4, 717.3)U/L, 41.2(29.6, 659.7)U/L, 6.3(3.6, 7.9)lg cps/ml, (11.3±2.4)mmol/L and 261.5(174.6, 349.1)μmol/L, respectively, P<0.05] at presentation; the adverse effects include nausea, fatigue, hyperkalemia, anorexia, constipation, hair loss and joint pains, and no discontinuation of antiviral treatment occurred in our series. Conclusion The albavir/gravir antiviral regimen in the treatment of patients with CHC and CRD is safe and efficacious, which warrants further clinical investigation.

Key words: Hepatitis C, Chronic renal disease, Albavir, Gravir, Therapy